skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 59,078  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
Material Type:
Article
Add to My Research

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Nature reviews. Immunology, 2021-10, Vol.21 (10), p.626-636 [Peer Reviewed Journal]

2021. Springer Nature Limited. ;COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/s41577-021-00592-1 ;PMID: 34373623

Full text available

2
Myocarditis With COVID-19 mRNA Vaccines
Material Type:
Article
Add to My Research

Myocarditis With COVID-19 mRNA Vaccines

Circulation (New York, N.Y.), 2021-08, Vol.144 (6), p.471-484 [Peer Reviewed Journal]

2021 American Heart Association, Inc. 2021 ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.121.056135 ;PMID: 34281357

Full text available

3
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Material Type:
Article
Add to My Research

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine, 2020-12, Vol.383 (27), p.2603-2615 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;COPYRIGHT 2020 Massachusetts Medical Society ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034577 ;PMID: 33301246

Digital Resources/Online E-Resources

4
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Material Type:
Article
Add to My Research

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

New England Journal of Medicine, 2021-06, Vol.384 (23), p.2187-2201 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2101544 ;PMID: 33882225

Digital Resources/Online E-Resources

5
The lightning-fast quest for COVID vaccines - and what it means for other diseases
Material Type:
Article
Add to My Research

The lightning-fast quest for COVID vaccines - and what it means for other diseases

Nature (London), 2021-01, Vol.589 (7840), p.16-18 [Peer Reviewed Journal]

ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-020-03626-1 ;PMID: 33340018

Full text available

6
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Material Type:
Article
Add to My Research

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine, 2021-05, Vol.384 (20), p.1885-1898 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2102214 ;PMID: 33725432

Digital Resources/Online E-Resources

7
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Material Type:
Article
Add to My Research

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

New England Journal of Medicine, 2021-05, Vol.384 (19), p.1824-1835 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034201 ;PMID: 33440088

Digital Resources/Online E-Resources

8
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Material Type:
Article
Add to My Research

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

New England Journal of Medicine, 2021-09, Vol.385 (13), p.1172-1183 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2107659 ;PMID: 34192426

Digital Resources/Online E-Resources

9
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
Material Type:
Article
Add to My Research

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

The Lancet (British edition), 2021-03, Vol.397 (10278), p.1023-1034 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2021 Elsevier B.V. ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00306-8 ;PMID: 33587887

Full text available

10
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Material Type:
Article
Add to My Research

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

The Lancet (British edition), 2021-09, Vol.398 (10303), p.856-869 [Peer Reviewed Journal]

2021 ;Crown Copyright © 2021 Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;Copyright Elsevier Limited Sep 4, 2021 ;Crown Copyright © 2021 Published by Elsevier Ltd. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01694-9 ;PMID: 34370971

Full text available

11
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Material Type:
Article
Add to My Research

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Nature reviews. Immunology, 2022-01, Vol.22 (1), p.57-65 [Peer Reviewed Journal]

2021. Springer Nature Limited. ;COPYRIGHT 2022 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/s41577-021-00662-4 ;PMID: 34876702

Full text available

12
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Material Type:
Article
Add to My Research

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Nature medicine, 2021-11, Vol.27 (11), p.2032-2040 [Peer Reviewed Journal]

2021. The Author(s). ;COPYRIGHT 2021 Nature Publishing Group ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01540-1 ;PMID: 34588689

Full text available

13
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Material Type:
Article
Add to My Research

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

The Lancet (British edition), 2021-05, Vol.397 (10289), p.2043-2046 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01115-6 ;PMID: 33991480

Full text available

14
Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
Material Type:
Article
Add to My Research

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

New England Journal of Medicine, 2021-11, Vol.385 (21), p.2010-2012 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc2115596 ;PMID: 34648703

Digital Resources/Online E-Resources

15
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Material Type:
Article
Add to My Research

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

The Lancet, 2020-12, Vol.396 (10267), p.1979-1993 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at http://creativecommons.org/licenses/by-nc-nd/4.0 ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32466-1 ;PMID: 33220855

Digital Resources/Online E-Resources

16
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
Material Type:
Article
Add to My Research

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations

Frontiers in immunology, 2021-04, Vol.12, p.669339-669339 [Peer Reviewed Journal]

Copyright © 2021 He, Mao, Zhang, Bian, Gao, Wang, Xu and Liang. ;Copyright © 2021 He, Mao, Zhang, Bian, Gao, Wang, Xu and Liang 2021 He, Mao, Zhang, Bian, Gao, Wang, Xu and Liang ;ISSN: 1664-3224 ;EISSN: 1664-3224 ;DOI: 10.3389/fimmu.2021.669339 ;PMID: 33912196

Full text available

17
Multisociety Statement on COVID-19 Vaccination as a Condition of Employment for Healthcare Personnel
Material Type:
Article
Add to My Research

Multisociety Statement on COVID-19 Vaccination as a Condition of Employment for Healthcare Personnel

Infection Control & Hospital Epidemiology, 2021-07, p.1 [Peer Reviewed Journal]

2021. Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the associated terms available at https://www.stm-assoc.org/about-the-industry/coronavirus-2019-ncov/. ;DOI: 10.1017/ice.2021.322

Digital Resources/Online E-Resources

18
How to redesign COVID vaccines so they protect against variants
Material Type:
Article
Add to My Research

How to redesign COVID vaccines so they protect against variants

Nature (London), 2021-02, Vol.590 (7844), p.15-16 [Peer Reviewed Journal]

Copyright Nature Publishing Group Feb 4, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-021-00241-6 ;PMID: 33514888

Full text available

19
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
Material Type:
Article
Add to My Research

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

The Lancet infectious diseases, 2021-12, Vol.21 (12), p.1654-1664 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(21)00396-0 ;PMID: 34324836

Full text available

20
Efficacy and safety of COVID-19 vaccines in older people
Material Type:
Article
Add to My Research

Efficacy and safety of COVID-19 vaccines in older people

Age and Ageing, 2021-03, Vol.50 (2), p.279-283 [Peer Reviewed Journal]

The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2020 ;The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://academic.oup.com/journals/pages/coronavirus . ;ISSN: 0002-0729 ;EISSN: 1468-2834 ;DOI: 10.1093/ageing/afaa274 ;PMID: 33320183

Digital Resources/Online E-Resources

Results 1 - 20 of 59,078  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (34,030)

Refine My Results

Creation Date 

From To
  1. Before 2017  (1)
  2. 2017 To 2017  (1)
  3. 2018 To 2018  (4)
  4. 2019 To 2020  (4,092)
  5. After 2020  (54,979)
  6. More options open sub menu

Language 

  1. English  (58,811)
  2. Japanese  (1,794)
  3. Portuguese  (230)
  4. French  (167)
  5. Spanish  (160)
  6. Norwegian  (50)
  7. Chinese  (41)
  8. German  (41)
  9. Turkish  (29)
  10. Korean  (23)
  11. Polish  (12)
  12. Italian  (12)
  13. Afrikaans  (11)
  14. Russian  (8)
  15. Romanian  (8)
  16. Indonesian  (7)
  17. Hungarian  (6)
  18. Arabic  (4)
  19. Croatian  (4)
  20. Dutch  (3)
  21. More options open sub menu

Searching Remote Databases, Please Wait